No Data
No Data
Sunshine Guojian Pharmaceutical (688336): Operation is stable, and the innovative self-developed drugs are about to enter the harvesting period.
In the event, Sunshine Guojian Pharmaceutical released its Q1 report for 2025, achieving revenue of 0.311 billion yuan in a single quarter, a year-on-year increase of 16.57%, with net income attributable to the parent company of 0.103 billion yuan, a year-on-year increase of 12.99%, and a non-recurring net income attributable to the parent company of 0.
Sansei Guojian: Sansei Guojian: Report for the first quarter of 2025
Sansei Guojian: Report for the first quarter of 2025
Sunshine Guojian Pharmaceutical: Q1 revenue grew by 16.6%, with several positive developments in the R&D pipeline.
Sunshine Guojian Pharmaceutical's Q1 revenue grew by 16.6%, with multiple positive developments in the R&D pipeline. Summary of key points: Financial performance: Q1 revenue in 2025 was 0.311 billion...
Sunshine Guojian Pharmaceutical (688336.SH): In the first quarter, the Net income was 0.103 billion yuan, an increase of 12.99% year-on-year.
Glory Times reported on April 22 that Sunshine Guojian Pharmaceutical (688336.SH) announced its first quarterly report for 2025, achieving revenue of 0.311 billion yuan during the reporting period, a year-on-year increase of 16.57%; net income attributable to shareholders of the listed company was 0.103 billion yuan, a year-on-year growth of 12.99%; the basic EPS was 0.17 yuan.
Express News | Star closing review: The Innovative Drugs sector leads the rise, while the Optics Optoelectronics and Software sectors perform actively.